When Can a Salvage Therapy (T-DM1) Take the Lead?

J Clin Oncol. 2016 Oct 10;34(29):3492-3494. doi: 10.1200/JCO.2016.68.4241.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Breast Neoplasms
  • Humans
  • Maytansine*
  • Receptor, ErbB-2
  • Salvage Therapy*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Maytansine
  • Receptor, ErbB-2
  • Trastuzumab